The path forward is not a dead end. It is simply a longer road.
For the one in three people with focal epilepsy whose seizures resist every medication tried, medicine has long offered a quiet resignation — a narrowing of hope with each failed drug. A new study published in JAMA Neurology gently but firmly pushes back against that resignation, finding that nearly seven in ten treatment-resistant patients experienced meaningful seizure reduction when followed over years rather than weeks. The research, drawn from an international cohort tracked by NYU neurologists, suggests that persistence in the face of apparent failure is not futile — it is, perhaps, the very nature of the work.
- One in three focal epilepsy patients faces a wall of failed medications, with seizures continuing despite exhausting standard treatment options — a reality that quietly erodes quality of life and clinical optimism alike.
- Conventional neurology has long treated repeated drug failure as a signal to lower expectations, leaving many patients and physicians without a clear reason to keep trying.
- A three-year study of nearly 150 treatment-resistant adults found 68% experienced fewer seizures over time, with 13% achieving at least three consecutive seizure-free months — numbers that directly contradict the field's prevailing assumptions.
- Crucially, the number of previously failed medications did not predict future outcomes, meaning a patient who had tried ten drugs was no worse positioned than one who had tried four.
- Newer anti-seizure medications approved in the last 15 years — including cenobamate and epidiolex — were among the most common therapies linked to improvement, pointing toward an evolving pharmaceutical landscape worth exploring.
- The findings are shifting clinical expectations: seizure relief in resistant cases may unfold over months or years, demanding patience from both patients and the physicians guiding their care.
For roughly one in three people living with focal epilepsy, the medications simply don't work. They try one drug, then another, then more — and still the seizures come. Neurology has long held that once a patient exhausts the usual treatments, the outlook dims considerably. A study published in JAMA Neurology on October 20 challenges that assumption directly.
Researchers from NYU Grossman School of Medicine, working within the international Human Epilepsy Project, followed nearly 150 adults who had already failed at least four anti-seizure medications. Tracking them for up to three years, the team found that 68 percent experienced a measurable reduction in seizure frequency during the study's second half compared to its first. Nearly 13 percent went at least three months without a seizure; about 8 percent stayed seizure-free for six months or longer.
Perhaps the most counterintuitive finding: the number of medications a patient had previously failed had no bearing on whether they would eventually improve. Someone who had tried ten drugs had the same prospects as someone who had tried four. The medications most associated with improvement — cenobamate, clobazam, eslicarbazepine, and epidiolex — were all approved within the past 15 years, underscoring the relevance of newer pharmaceutical options.
Lead author Dr. Ojas Potnis called the findings a challenge to the assumption that repeated drug failure makes further effort not worth pursuing. His co-senior author, Dr. Jacqueline French, urged clinicians to keep searching regardless of how many therapies a patient has already tried. One open question remains: whether the gradual improvements stem from the treatments themselves or from the disease's natural evolution over time. But the practical message is unambiguous — for those who haven't responded to initial care, the road ahead is longer than once believed, not closed.
For roughly one in three people living with focal epilepsy, the standard medications simply don't work. They try one drug, then another, then a third and fourth—and still the seizures come. The conventional wisdom in neurology has long held that once a patient exhausts the usual arsenal of anti-seizure treatments, the outlook darkens considerably. But a new study published in JAMA Neurology on October 20 challenges that assumption with evidence suggesting that even those labeled "treatment-resistant" may find meaningful relief if they keep searching.
Focal epilepsy, the most prevalent form of the disorder, begins in a single region of the brain where nerve cells suddenly fire in an uncontrolled burst of electrical activity. The seizures that result can take many forms—sudden behavioral changes, unexpected emotional shifts, or strange physical sensations—but they all originate from that one focal point. For most people, anti-seizure medications bring the condition under control. For others, the drugs fail to prevent seizures no matter how many are tried.
Researchers from NYU Grossman School of Medicine, working as part of the international Human Epilepsy Project, followed nearly 150 adults who had already tried at least four different anti-seizure medications without success. Some of these patients also had implantable devices designed to interrupt seizures. The team tracked them for up to three years, monitoring whether their seizure patterns changed over time. The results were striking: 68 percent of participants experienced a measurable reduction in how often they seized during the second half of the study compared to the first half. This directly contradicts the long-held belief that patients who fail a handful of medications have little reason to hope for improvement.
The gains, while real, were gradual. The medications did not typically eliminate seizures altogether, but they did appear to stretch the time between episodes. Nearly 13 percent of participants managed to go at least three months without a seizure. Almost 8 percent stayed seizure-free for six months or longer. Three percent achieved a full year or more without any seizures. These percentages may sound modest, but they represent a significant shift from earlier research that followed patients for only three months. The implication is clear: seizure reduction in treatment-resistant cases is a slow process that requires patience and persistence.
One of the study's most counterintuitive findings was that the number of medications a patient had already failed bore no relationship to whether they would eventually improve. A person who had tried four drugs had the same chances as someone who had tried ten. This suggests that hitting a wall with earlier treatments does not foreclose future possibilities. The four anti-seizure medications most commonly used by patients who did improve—cenobamate, clobazam, eslicarbazepine, and epidiolex—were all approved within the past 15 years, pointing to the value of newer pharmaceutical options. Whether patients had an implantable device also made no difference to their seizure trajectory.
Dr. Ojas Potnis, the study's lead author and a neurology resident at NYU, emphasized the shift in thinking this research demands. "Our findings challenge the assumption that once a patient with focal epilepsy has failed a certain number of anti-seizure drugs, their chances of finding relief are small and not worth the effort," he said. His co-senior author, Dr. Jacqueline French, a neurologist and professor at the same institution, added that the results "offer hope that focal epilepsy will get better over time for most people," and urged clinicians to continue searching for the right treatment regimen regardless of how many therapies patients might need to try.
One question remains unanswered: whether the gradual seizure reduction observed in the study resulted from the therapeutic interventions themselves—more than half of those who improved started a new medication during the monitoring period—or from the natural evolution of the disease over time. That distinction matters for understanding the mechanism at work. Still, the practical message is clear. For the millions of people with focal epilepsy who have not responded to initial treatments, the path forward is not a dead end. It is simply a longer road than clinicians once believed.
Citas Notables
Our findings challenge the assumption that once a patient with focal epilepsy has failed a certain number of anti-seizure drugs, their chances of finding relief are small and not worth the effort.— Dr. Ojas Potnis, lead author, NYU Grossman School of Medicine
Health care providers should keep searching for the best treatment regimen for their patients no matter how many therapies they may need to try.— Dr. Jacqueline French, co-senior author, NYU Grossman School of Medicine
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that 68 percent saw improvement if the improvements were so small—three months seizure-free, or six months?
Because for someone living with unpredictable seizures, three months of safety is not small. It's the difference between being able to plan a trip, hold a job, or feel like your life is your own. And the study suggests that patience compounds these gains.
But the study doesn't actually prove the drugs caused the improvement, right? It could just be the disease burning itself out.
Correct. That's the honest uncertainty here. But from a patient's perspective, it doesn't matter much. If trying a new medication correlates with seizure reduction, that's actionable information. The mechanism matters for science; the outcome matters for living.
Why did the number of previously failed drugs have no predictive power? That seems counterintuitive.
It suggests that treatment-resistant epilepsy isn't a fixed category—it's more like a puzzle where the answer depends on finding the right combination, not on how many wrong answers you've already tried. Each person's brain chemistry is different.
What about the patients who saw no improvement at all? The study doesn't say much about them.
That's the gap. Thirty-two percent of the group didn't improve. The study doesn't explain why some brains respond and others don't. That's the next question neurology needs to answer.
Does this change how doctors should treat these patients?
It should. It says: don't give up after four medications. Don't assume the case is closed. Keep trying, especially with newer drugs. The timeline is measured in years, not weeks.